Skip to main content

3 Result(s)

within Maximilian Gassenmaier Remove this filter

and

  1. No Access

    Article

    Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors

    Hepatic immune-related adverse events (irAE) including elevated liver function tests (transaminases) occur in 1.4–22.3% of melanoma patients receiving immune checkpoint inhibitors (ICPI) and constitute a poten...

    Johanna Winter, Max M. Lenders, Maximilian Gassenmaier… in Cancer Immunology, Immunotherapy (2021)

  2. Article

    Open Access

    Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors

    Despite impressive response rates, most patients with advanced melanoma ultimately progress following therapy with B-Raf proto-oncogene (BRAF) inhibitors (BRAFi). Therefore, frequent radiologic assessments are...

    Maximilian Gassenmaier, Max M. Lenders, Andrea Forschner… in Targeted Oncology (2021)

    Download PDF (1177 KB) View Article

  3. No Access

    Article

    Safety of shortened infusion times for combined ipilimumab and nivolumab

    Combined ipilimumab and nivolumab induces encouraging response rates in patients with unresectable or metastatic melanoma. However, the approved protocol for dual checkpoint inhibition (3 mg/kg ipilimumab over...

    Maximilian Gassenmaier, Hans-Peter Lipp… in Cancer Immunology, Immunotherapy (2018)